{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:55:38Z","timestamp":1789685738859,"version":"4.0.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LBY24H180004"],"award-info":[{"award-number":["LBY24H180004"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007834","name":"Ningbo Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["2023J384"],"award-info":[{"award-number":["2023J384"]}],"id":[{"id":"10.13039\/100007834","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Colloids and Surfaces B: Biointerfaces"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.colsurfb.2026.115416","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:09:21Z","timestamp":1767859761000},"page":"115416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Esterase-activatable dimeric HDAC inhibitor nanotherapeutics for enhanced lymphoma epigenetic therapy"],"prefix":"10.1016","volume":"261","author":[{"given":"Tongyu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanchuan","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.colsurfb.2026.115416_bib1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.16914","article-title":"Epigenetic targeting in lymphoma","volume":"192","author":"Booth","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115416_bib2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.colsurfb.2026.115416_bib3","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries, CA: a cancer","volume":"71","author":"Sung","year":"2021","journal-title":"J. Clin."},{"issue":"6","key":"10.1016\/j.colsurfb.2026.115416_bib4","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/annonc\/mdv019","article-title":"Genetic lesions in diffuse large B-cell lymphomas","volume":"26","author":"Testoni","year":"2015","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"15","key":"10.1016\/j.colsurfb.2026.115416_bib5","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-Cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.colsurfb.2026.115416_bib6","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ctrv.2015.05.007","article-title":"Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas","volume":"41","author":"P\u00e9rez-Callejo","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.colsurfb.2026.115416_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12943-015-0474-2","article-title":"Novel drug targets for personalized precision medicine in relapsed\/refractory diffuse large B-cell lymphoma: a comprehensive review","volume":"14","author":"Camicia","year":"2015","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.colsurfb.2026.115416_bib8","article-title":"Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: a systematic review","volume":"13","author":"Tian","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115416_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01085-9","article-title":"Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years","volume":"14","author":"Berning","year":"2024","journal-title":"Blood Cancer J."},{"issue":"4","key":"10.1016\/j.colsurfb.2026.115416_bib10","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41591-025-03532-x","article-title":"An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma","volume":"31","author":"Raj","year":"2025","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.colsurfb.2026.115416_bib11","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3324\/haematol.2023.283002","article-title":"Results from a phase I trial of pembrolizumab plus vorinostat in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"109","author":"Godfrey","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.colsurfb.2026.115416_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009099","article-title":"Cantharidin overcomes IL-2R\u03b1 signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species","volume":"12","author":"Zhu","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.colsurfb.2026.115416_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117852","article-title":"Design, synthesis, and biological evaluation of novel PI3K\u03b4\/HDAC6 dual inhibitors for the treatment of non-Hodgkin's lymphoma","volume":"296","author":"Zuo","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.colsurfb.2026.115416_bib14","article-title":"Clinical efficacy and mechanistic insights of FDA-approved HDAC inhibitors in the treatment of lymphoma","volume":"208","author":"El Omari","year":"2025","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"issue":"8","key":"10.1016\/j.colsurfb.2026.115416_bib15","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1021\/acs.accounts.3c00801","article-title":"Chemical versatility in catalysis and inhibition of the Class IIb histone deacetylases","volume":"57","author":"Christianson","year":"2024","journal-title":"Acc. Chem. Res."},{"issue":"43","key":"10.1016\/j.colsurfb.2026.115416_bib16","doi-asserted-by":"crossref","first-page":"14328","DOI":"10.1523\/JNEUROSCI.1010-14.2014","article-title":"Hydroxamic acid-based histone deacetylase (HDAC) inhibitors can mediate neuroprotection independent of HDAC inhibition","volume":"34","author":"Sleiman","year":"2014","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"issue":"3","key":"10.1016\/j.colsurfb.2026.115416_bib17","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1021\/jacsau.4c01148","article-title":"Discovery of De Novo macrocycle inhibitors of Histone Deacetylase 11","volume":"5","author":"Dankov\u00e1","year":"2025","journal-title":"JACS Au"},{"issue":"12","key":"10.1016\/j.colsurfb.2026.115416_bib18","doi-asserted-by":"crossref","first-page":"7698","DOI":"10.1021\/acs.jmedchem.3c00226","article-title":"The zinc-binding group effect: lessons from non-hydroxamic acid vorinostat analogs","volume":"66","author":"Geurs","year":"2023","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.colsurfb.2026.115416_bib19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4155\/fmc.12.3","article-title":"Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed","volume":"4","author":"Gryder","year":"2012","journal-title":"Future Med. Chem."},{"issue":"8","key":"10.1016\/j.colsurfb.2026.115416_bib20","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.xphs.2024.05.025","article-title":"Development of new nanoniosome carriers for vorinostat: evaluation of anticancer efficacy in vitro","volume":"113","author":"Nazari-Vanani","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.colsurfb.2026.115416_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2020.111523","article-title":"Enhanced cellular uptake and cytotoxicity of vorinostat through encapsulation in TPGS-modified liposomes","volume":"199","author":"Farooq","year":"2021","journal-title":"Colloids Surf. B"},{"issue":"2","key":"10.1016\/j.colsurfb.2026.115416_bib22","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s13346-023-01415-7","article-title":"Exploring the synergistic behavior of paclitaxel and vorinostat upon co-loading in albumin nanoparticles for breast cancer management","volume":"14","author":"Abhang","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"issue":"9","key":"10.1016\/j.colsurfb.2026.115416_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092558","article-title":"Prolonging the half-life of histone deacetylase inhibitor Belinostat via 50 nm scale liposomal subcutaneous delivery system for peripheral T-Cell lymphoma","volume":"12","author":"Cheng","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.colsurfb.2026.115416_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40824-022-00249-7","article-title":"Combinatorial nanococktails via self-assembling lipid prodrugs for synergistically overcoming drug resistance and effective cancer therapy","volume":"26","author":"Li","year":"2022","journal-title":"Biomater. Res."},{"issue":"11","key":"10.1016\/j.colsurfb.2026.115416_bib25","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2217\/nnm-2017-0316","article-title":"Unified D-\u03b1-Tocopherol 5-Fu\/SAHA bioconjugates self-assemble as complex nanodrug for optimized combination therapy","volume":"13","author":"Han","year":"2018","journal-title":"Nanomedicine"},{"key":"10.1016\/j.colsurfb.2026.115416_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120705","article-title":"Tuning the efficacy of esterase-activatable prodrug nanoparticles for the treatment of colorectal malignancies","volume":"270","author":"Wang","year":"2021","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.colsurfb.2026.115416_bib27","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.colsurfb.2026.115416_bib28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s13402-023-00882-x","article-title":"Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer","volume":"47","author":"Finnegan","year":"2024","journal-title":"Cell. Oncol."},{"issue":"18","key":"10.1016\/j.colsurfb.2026.115416_bib29","doi-asserted-by":"crossref","first-page":"20960","DOI":"10.1021\/acsami.0c22587","article-title":"\u03b2-Cyclodextrin-poly (\u03b2-Amino Ester) nanoparticles are a generalizable strategy for high loading and sustained release of HDAC inhibitors","volume":"13","author":"Chaudhuri","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"18","key":"10.1016\/j.colsurfb.2026.115416_bib30","first-page":"20960","article-title":"Advances and challenges of HDAC inhibitors in cancer therapeutics","volume":"138","author":"McClure","year":"2021","journal-title":"Adv. Cancer Res."},{"issue":"Pt 2","key":"10.1016\/j.colsurfb.2026.115416_bib31","article-title":"Histone deacetylase inhibiting nanoprodrugs for enhanced chemodynamic therapy through multistage downregulating glutathione","volume":"305","author":"Liu","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.colsurfb.2026.115416_bib32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.actbio.2020.07.007","article-title":"Dimerization-induced self-assembly of a redox-responsive prodrug into nanoparticles for improved therapeutic index","volume":"113","author":"Zhou","year":"2020","journal-title":"Acta Biomater."},{"issue":"6","key":"10.1016\/j.colsurfb.2026.115416_bib33","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.7150\/ijbs.79654","article-title":"Loss of HRD functional phenotype impedes immunotherapy and can be reversed by HDAC inhibitor in ovarian cancer","volume":"19","author":"Yang","year":"2023","journal-title":"Int. J. Biol. Sci."}],"container-title":["Colloids and Surfaces B: Biointerfaces"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776526000044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0927776526000044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T23:53:28Z","timestamp":1773964408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0927776526000044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":33,"alternative-id":["S0927776526000044"],"URL":"https:\/\/doi.org\/10.1016\/j.colsurfb.2026.115416","relation":{},"ISSN":["0927-7765"],"issn-type":[{"value":"0927-7765","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Esterase-activatable dimeric HDAC inhibitor nanotherapeutics for enhanced lymphoma epigenetic therapy","name":"articletitle","label":"Article Title"},{"value":"Colloids and Surfaces B: Biointerfaces","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.colsurfb.2026.115416","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115416"}}